Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 640,219
  • Shares Outstanding, K 52,520
  • Annual Sales, $ 1,044 M
  • Annual Income, $ -190,600 K
  • EBIT $ 184 M
  • EBITDA $ 300 M
  • 60-Month Beta 2.32
  • Price/Sales 0.62
  • Price/Cash Flow 5.94
  • Price/Book 1.03

Options Overview Details

View History
  • Implied Volatility 72.42% (-17.53%)
  • Historical Volatility 64.12%
  • IV Percentile 20%
  • IV Rank 3.44%
  • IV High 509.14% on 04/04/25
  • IV Low 56.85% on 05/21/25
  • Expected Move (DTE 2) 0.67 (5.51%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 634
  • Volume Avg (30-Day) 578
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 17,246
  • Open Int (30-Day) 17,381
  • Expected Range 11.52 to 12.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.05
  • Growth Rate Est. (year over year) +1,997,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.02 +35.14%
on 11/21/25
12.63 -3.48%
on 12/16/25
+2.08 (+20.57%)
since 11/14/25
3-Month
7.75 +57.29%
on 09/17/25
13.41 -9.10%
on 10/30/25
+4.36 (+55.68%)
since 09/16/25
52-Week
4.02 +203.23%
on 04/09/25
13.41 -9.10%
on 10/30/25
+3.32 (+37.43%)
since 12/16/24

Most Recent Stories

More News
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License...

EBS : 12.19 (-1.14%)
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® (naloxone...

EBS : 12.19 (-1.14%)
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November...

EBS : 12.19 (-1.14%)
Emergent Biosolutions: Q3 Earnings Snapshot

Emergent Biosolutions: Q3 Earnings Snapshot

EBS : 12.19 (-1.14%)
Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025...

EBS : 12.19 (-1.14%)
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

GAITHERSBURG, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new survey 1 of approximately 250 U.S. policy opinion leaders showing that...

EBS : 12.19 (-1.14%)
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial...

EBS : 12.19 (-1.14%)
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc....

EBS : 12.19 (-1.14%)
3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts

Discover three low P/E small-cap stocks with bullish analyst sentiment and growth potential in a lower interest rate environment

INVE : 3.52 (+0.28%)
EBS : 12.19 (-1.14%)
IMMR : 6.72 (-0.44%)
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product...

EBS : 12.19 (-1.14%)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 13.07
2nd Resistance Point 12.85
1st Resistance Point 12.52
Last Price 12.19
1st Support Level 11.97
2nd Support Level 11.75
3rd Support Level 11.42

See More

52-Week High 13.41
Last Price 12.19
Fibonacci 61.8% 9.82
Fibonacci 50% 8.71
Fibonacci 38.2% 7.61
52-Week Low 4.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar